REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 17 2016 - 4:01PM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated (AAV) gene therapy based on its
proprietary NAV® Technology Platform (NAV), today announced that
President and CEO Kenneth T. Mills will present as part of the Gene
Therapy Panel at the 28th Annual Piper Jaffray Healthcare
Conference. The panel will take place on Wednesday, November 30,
2016 at 10:00 a.m. ET at the Lotte New York Palace in New York
City. In addition, REGENXBIO representatives will be holding
one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s
NAV® Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO’s NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform licensees. As of September 30, 2016,
REGENXBIO’s NAV Technology Platform was being applied in the
development of 29 product candidates for a variety of diseases,
including five internally developed candidates and 24 partnered
candidates developed by REGENXBIO’s licensees.
Investors
Heather Savelle, 646-395-3734
heather@argotpartners.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024